Federal Circuit Affirms Patent Trial And Appeal Board Decision, Finding Claims Of Patents Covering CRISPR Guide RNA Technology As Anticipated And Obvious

On June 11, 2025, the United States Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board (PTAB) decision invalidating two patents owned by Agilent Technologies. The patents at issue, U.S. Patent Nos. 10,337,001 and 10,900,034, claim synthetic CRISPR guide RNAs with specific chemical modifications intended to improve stability and functionality. This CRISPR-Cas system enables targeted DNA cleavage, with the gRNA (composed of crRNA and tracrRNA, or as a…
By: A&O Shearman